Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice: A propensity-matched analysis of 76,940 patients

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to warfarin. This retrospective study used four large US claims databases (MarketScan, PharMetrics, Optum, and Humana) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoyan, Deitelzweig, Steve, Keshishian, Allison, Hamilton, Melissa, Horblyuk, Ruslan, Gupta, Kiran, Luo, Xuemei, Mardekian, Jack, Friend, Keith, Nadkarni, Anagha, Pan, Xianying, Lip, Gregory Y. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Schattauer GmbH 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291856/
https://www.ncbi.nlm.nih.gov/pubmed/28300870
http://dx.doi.org/10.1160/TH17-01-0068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291856/
https://www.ncbi.nlm.nih.gov/pubmed/28300870
http://dx.doi.org/10.1160/TH17-01-0068

Ejemplares similares